Takeda's Zasocitinib Shows Rapid, Durable Skin Clearance In Phase 3 Psoriasis Trials

Takeda announced new data from two pivotal Phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis, highlighting once-daily dosing potential. The update strengthens Takeda's late-stage biotech pipeline and, pending full data release and regulatory steps, could modestly boost the stock (low single-digit percentage moves) as the program advances toward commercialization.

Analysis

Takeda announced new data from two pivotal Phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis, highlighting once-daily dosing potential. The update strengthens Takeda's late-stage biotech pipeline and, pending full data release and regulatory steps, could modestly boost the stock (low single-digit percentage moves) as the program advances toward commercialization.